Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston scientific

ISIN: US1011371077 , WKN: 884113

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?

2025-09-26
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.

Phibro Animal Health Stock Surges 82.1% YTD: What's Fueling It?

2025-09-25
PAHC rallies 82% YTD with booming vaccines, MFAs and global expansion fueling investor confidence.

PAHC vs. BSX: Which Stock Is the Better Value Option?

2025-09-24
PAHC vs. BSX: Which Stock Is the Better Value Option?

Single-use Duodenoscope Market Forecasts and Competitive Strategies Report 2025-2033: Ambu and Boston Scientific Lead with Innovation and Infection-Free Solutions

2025-09-24
The single-use duodenoscope market is poised for rapid growth due to increased emphasis on patient safety and infection control. Single-use devices prevent cross-contamination, offering a safer alternative to reusable models. However, costs and technological adoption remain challenges, particularly in budget-constrained regions. Key opportunities lie in expanding direct and indirect sales channels, targeting hospitals and ASCs, with notable market expansion expected in North America, Europe, and

Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?

2025-09-24
Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.

Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions

2025-09-23
BOSTON, MA / ACCESS Newswire / September 23, 2025 / MEDevice Boston , the premier MedTech event connecting top OEMs (Original Equipment Manufacturers) with emerging suppliers and strategic partners, has announced its lineup of distinguished keynote ...

Does Boston Scientific’s Recent Dip Signal Opportunity After NEuwave Expansion in 2025?

2025-09-23
If you’re on the fence about what to do with Boston Scientific stock, you’re not alone. Plenty of investors are taking a hard look at the recent numbers and wondering whether this is a moment to buy in or sit tight. Over the past month, shares have dipped 8.6%, giving back some of the impressive gains racked up over the last few years. However, taking a broader view reveals a stock that is up more than 150% over both three and five years, with an 8.6% gain year to date and a 15.5% jump over...

Nvidia Is One Of 10 Stocks Analysts Insist Are Screaming Buys Now

2025-09-22
Nvidia gets attention from investors — and for good reason. But it only ranks tenth among S&P 500 stocks analysts like.

Boston Scientific Corporation (BSX) Expands AI-Enhanced Heart Devices With FARAPULSE Approval

2025-09-21
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Boston Scientific Corporation is one of them Boston Scientific Corporation (NYSE:BSX) is emerging as a top AI-powered biotech stock by embedding artificial intelligence into its medical device portfolio, particularly in cardiology. Its AI strategy focuses on integrating advanced […]

Boston Scientific Likely to Issue Long-Term Organic Revenue Growth Outlook Higher Than Previous Target, Needham Says

2025-09-19
Boston Scientific (BSX) is expected to provide a long-term organic revenue growth outlook at its upc